Prognostic Value of MTV and TLG of ¹⁸F-FDG PET in Patients with Stage I and II Non-Small-Cell Lung Cancer: a Meta-Analysis

Table 3

Subgroup of PFS of MTV and OS of TLG.

Endpoint	Volumetric parameters	Factor	No. of studies	Heterogeneity test (I^2, )	Effect model	HR	95% CI of HR	Conclusion
PFS	MTV	Region
		Asian	3	0.0, 0.606	Fixed	3.22	1.84, 5.62	Significant
		European	1	—	—	3.29	1.27, 8.52	Significant
		American	1			1.66	0.44, 8.1	Insignificant
		Cut-off method
		ROC	1	—	—	4.07	1.25, 13.25	Significant
		Others	4	0.0, 0.703	Fixed	2.89	1.75, 4.75	Significant
		Analysis method
		Multivariate analysis	2	0.0, 0.370	Fixed	3.01	1.59, 5.67	Significant
		Univariate analysis	3	0.0, 0.644	Fixed	3.08	1.58, 5.99	Significant
OS	TLG	Region
		Asian	4	0.0, 0.455	Fixed	2.17	1.46, 3.23	Significant
		American	1	—	—	2.13	0.75, 6.04	Insignificant
		Cut-off method
		ROC	1	—	—	3.73	0.84, 16.51	Insignificant
		Others	4	0.0, 0.559	Fixed	2.09	1.42, 3.07	Significant
		Analysis method
		Multivariate analysis	3	0.0, 0.890	Fixed	2.85	1.68, 4.83	Significant
		Univariate analysis	2	0.0, 0.577	Fixed	1.65	0.97, 2.79	Insignificant

HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; OS, overall survival; MTV, metabolic tumor volume; TLG, total lesion glycolysis; ROC, receiver operating characteristic.